Skip to main content
Springer Nature Link
Log in

Extrapyramidal Symptoms with Atypical Antipsychotics

Incidence, Prevention and Management

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

The treatment of schizophrenia changed drastically with the discovery of antipsychotic medications in the 1950s, the release of clozapine in the US in 1989 and the subsequent development of the atypical or novel antipsychotics. These newer medications differ from their conventional counterparts, primarily based on their reduced risk of extrapyramidal symptoms (EPS). EPS can be categorised as acute (dystonia, akathisia and parkinsonism) and tardive (tardive dyskinesia and tardive dystonia) syndromes. They are thought to have a significant impact on subjective tolerability and adherence with antipsychotic therapy in addition to impacting function. Unlike conventional antipsychotic medications, atypical antipsychotics have a significantly diminished risk of inducing acute EPS at recommended dose ranges. These drugs may also have a reduced risk of causing tardive dyskinesia and in some cases may have the ability to suppress pre-existing tardive dyskinesia.

This paper reviews the available evidence regarding the incidence of acute EPS and tardive syndromes with atypical antipsychotic therapy. Estimates of incidence are subject to several confounds, including differing methods for detection and diagnosis of EPS, pretreatment effects and issues surrounding the administration of antipsychotic medications. The treatment of acute EPS and tardive dyskinesia now includes atypical antipsychotic therapy itself, although other adjunctive strategies such as antioxidants have also shown promise in preliminary trials.

The use of atypical antipsychotics as first line therapy for the treatment of schizophrenia is based largely on their reduced risk of EPS compared with conventional antipsychotics. Nevertheless, EPS with these drugs can occur, particularly when prescribed at high doses. The EPS advantages offered by the atypical antipsychotics must be balanced against other important adverse effects, such as weight gain and diabetes mellitus, now known to be associated with these drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Remington G, Kapur S. D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. J Clin Psychiatry 1999; 60: 15–9

    PubMed  CAS  Google Scholar 

  2. Hippius H. A historical perspective of clozapine. J Clin Psychiatry 1999; 60: 22–3

    Article  PubMed  Google Scholar 

  3. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96

    Article  PubMed  CAS  Google Scholar 

  4. Covell NH, Jackson CT, Evans AC, et al. Antipsychotic prescribing practices in Connecticut’s public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 2002; 28: 17–29

    Article  PubMed  Google Scholar 

  5. Weissman EM. Antipsychotic prescribing practices in the Veterans Healthcare Administration: New York metropolitan region. Schizophr Bull 2002; 28: 31–42

    Article  PubMed  Google Scholar 

  6. Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull 1997; 23: 663–74

    Article  PubMed  CAS  Google Scholar 

  7. Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others? Psychopharmacology (Berl) 2000; 148: 3–15

    Article  CAS  Google Scholar 

  8. Fleischhacker WW, Meise U, Gunther V, et al. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand Suppl 1994; 382: 11–5

    PubMed  CAS  Google Scholar 

  9. Hummer MF, Fleischhacker WW. Compliance and outcome in patients treated with antipsychotics: the impact of extrapyramidal syndromes. CNS Drugs 1996; 5: 13–20

    Article  Google Scholar 

  10. Shriqui CL, Bradwejn J, Jones BD. Tardive dyskinesia: legal and preventive aspects. Can J Psychiatry 1990; 35: 576–80

    PubMed  CAS  Google Scholar 

  11. Slovenko R. Update on legal issues associated with tardive dyskinesia. J Clin Psychiatry 2000; 61: 45–57

    PubMed  Google Scholar 

  12. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–6

    Article  PubMed  CAS  Google Scholar 

  13. Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581–9

    Article  PubMed  CAS  Google Scholar 

  14. Ayd F. A survey of drug-induced extrapyramidal reactions. JAMA 1961; 175: 1054–60

    Article  PubMed  CAS  Google Scholar 

  15. Wirshing WC. Movement disorders associated with neuroleptic treatment. J Clin Psychiatry 2001; 62Suppl. 21: 15–8

    PubMed  CAS  Google Scholar 

  16. Casey DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res 1999; 35Suppl.: S61–6

    Article  PubMed  Google Scholar 

  17. van Harten PN, Kahn RS. Tardive dystonia. Schizophr Bull 1999; 25: 741–8

    Article  PubMed  Google Scholar 

  18. Adityanjee, Aderibigbe YA, Jampala VC, et al. The current status of tardive dystonia. Biol Psychiatry 1999; 45: 715–30

    Article  PubMed  CAS  Google Scholar 

  19. Simpson GM. The treatment of tardive dyskinesia and tardive dystonia. J Clin Psychiatry 2000; 61Suppl. 4: 39–44

    PubMed  CAS  Google Scholar 

  20. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672–6

    Article  PubMed  CAS  Google Scholar 

  21. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11–9

    Article  PubMed  CAS  Google Scholar 

  22. Lane RD, Glazer WM, Hansen TE, et al. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J Nerv Ment Dis 1985; 173: 353–7

    Article  PubMed  CAS  Google Scholar 

  23. Chouinard G, Ross-Chouinard A, Annable L, et al. Extrapyramidal Symptom Rating Scale [abstract]. Can J Neurol Sci 1980; 7: 233

    Google Scholar 

  24. Claghorn J, Honigfeld G, Abuzzahab Sr FS, et al. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7: 377–84

    Article  PubMed  CAS  Google Scholar 

  25. Wahlbeck K, Cheine M, Essali A, et al. Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999; 156: 990–9

    PubMed  CAS  Google Scholar 

  26. Dave M. Clozapine-related tardive dyskinesia. Biol Psychiatry 1994; 35: 886–7

    Article  PubMed  CAS  Google Scholar 

  27. Kumet R, Freeman MP. Clozapine and tardive dyskinesia. J Clin Psychiatry 2002; 63: 167–8

    Article  PubMed  Google Scholar 

  28. Miller del D. Clozapine and tardive dyskinesia [letter]. Am J Psychiatry 2003; 160: 588

    Article  PubMed  Google Scholar 

  29. Gafoor R, Brophy J. Three case reports of emergent dyskinesia with clozapine. Eur Psychiatry 2003; 18: 260–1

    Article  PubMed  Google Scholar 

  30. Kane JM, Woerner MG, Pollack S, et al. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993; 54: 327–30

    PubMed  CAS  Google Scholar 

  31. Simpson GM, Lee JH, Shrivastava RK. Clozapine in tardive dyskinesia. Psychopharmacology (Berl) 1978; 56: 75–80

    Article  CAS  Google Scholar 

  32. Small JG, Milstein V, Marhenke JD, et al. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. J Clin Psychiatry 1987; 48: 263–7

    PubMed  CAS  Google Scholar 

  33. Littrell K, Magill AM. The effect of clozapine on preexisting tardive dyskinesia. J Psychosoc Nurs Ment Health Serv 1993; 31: 14–8

    PubMed  CAS  Google Scholar 

  34. Tamminga CA, Thaker GK, Moran M, et al. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994; 55Suppl. B: 102–6

    PubMed  Google Scholar 

  35. Spivak B, Mester R, Abesgaus J, et al. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997; 58: 318–22

    Article  PubMed  CAS  Google Scholar 

  36. Bassitt DP, Louza Neto MR. Clozapine efficacy in tardive dyskinesia in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 1998; 248: 209–11

    Article  PubMed  CAS  Google Scholar 

  37. Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158: 503–10

    Article  PubMed  CAS  Google Scholar 

  38. Van Harten PN, Kampuis DJ, Matroos GE. Use of clozapine in tardive dystonia. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 263–74

    Article  PubMed  Google Scholar 

  39. Larach VW, Zamboni RT, Mancini HR, et al. New strategies for old problems: tardive dyskinesia (TD): review and report on severe TD cases treated with clozapine, with 12, 8 and 5 years of video follow-up. Schizophr Res 1997; 28: 231–46

    Article  PubMed  CAS  Google Scholar 

  40. Karp BI, Goldstein SR, Chen R, et al. An open trial of clozapine for dystonia. Mov Disord 1999; 14: 652–7

    Article  PubMed  CAS  Google Scholar 

  41. Ahmed S, Chengappa KN, Naidu VR, et al. Clozapine withdrawal-emergent dystonias and dyskinesias: a case series. J Clin Psychiatry 1998; 59: 472–7

    Article  PubMed  CAS  Google Scholar 

  42. Uzun O, Cansever A, Ozsahin A. A case of relapsed tardive dyskinesia due to clozapine dose reduction. Int Clin Psychopharmacol 2001; 16: 369–71

    Article  PubMed  CAS  Google Scholar 

  43. Yovtcheva SP, Stanley-Tilt C, Moles JK. Reemergence of tardive dyskinesia after discontinuation of clozapine treatment. Schizophr Res 2000; 46: 107–9

    Article  PubMed  CAS  Google Scholar 

  44. Bowden CR, Voina SJ, Woestenborghs R, et al. Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro. J Pharmacol Exp Ther 1992; 262: 699–706

    PubMed  CAS  Google Scholar 

  45. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25–40

    Article  PubMed  CAS  Google Scholar 

  46. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825–35

    PubMed  CAS  Google Scholar 

  47. Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1997; 17: 194–201

    Article  PubMed  CAS  Google Scholar 

  48. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995; 166: 712–26

    Article  PubMed  CAS  Google Scholar 

  49. Kopala LC, Good KP, Honer WG. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. J Clin Psychopharmacol 1997; 17: 308–13

    Article  PubMed  CAS  Google Scholar 

  50. Love RC, Conley RR, Kelly DL, et al. A dose-outcome analysis of risperidone. J Clin Psychiatry 1999; 60: 771–5

    Article  PubMed  CAS  Google Scholar 

  51. Addington DE, Toews JA, Addington JM. Risperidone and tardive dyskinesia: a case report. J Clin Psychiatry 1995; 56: 484–5

    PubMed  CAS  Google Scholar 

  52. Woerner MG, Sheitman BB, Lieberman JA, et al. Tardive dyskinesia induced by risperidone? [letter]. Am J Psychiatry 1996; 153: 843

    PubMed  CAS  Google Scholar 

  53. Buzan RD. Risperidone-induced tardive dyskinesia. Am J Psychiatry 1996; 153: 734–5

    PubMed  CAS  Google Scholar 

  54. Feeney DJ, Klykylo W. Risperidone and tardive dyskinesia. J Am Acad Child Adolesc Psychiatry 1996; 35: 1421–2

    Article  PubMed  CAS  Google Scholar 

  55. Saran BM. Risperidone-induced tardive dyskinesia. J Clin Psychiatry 1998; 59: 29–30

    Article  PubMed  CAS  Google Scholar 

  56. Silberbauer C. Risperidone-induced tardive dyskinesia. Pharmacopsychiatry 1998; 31: 68–9

    Article  PubMed  CAS  Google Scholar 

  57. Lykouras L, Yannakis R, Hatzimanolis J, et al. Two cases of risperidone-induced tardive dyskinesia and a review of the literature. Eur Psychiatry 1999; 14: 245–7

    Article  PubMed  CAS  Google Scholar 

  58. Hong KS, Cheong SS, Woo JM, et al. Risperidone-induced tardive dyskinesia [letter]. Am J Psychiatry 1999; 156: 1290

    PubMed  CAS  Google Scholar 

  59. Krebs MO, Olie JP. Tardive dystonia induced by risperidone. Can J Psychiatry 1999; 44: 507–8

    PubMed  CAS  Google Scholar 

  60. Spivak M, Smart M. Tardive dyskinesia from low-dose risperidone [letter]. Can J Psychiatry 2000; 45: 202

    PubMed  CAS  Google Scholar 

  61. Bassitt DP, de Souza Lobo Garcia L. Risperidone-induced tardive dyskinesia. Pharmacopsychiatry 2000; 33: 155–6

    Article  PubMed  CAS  Google Scholar 

  62. Narendran R, Young CM, Pato MT. Possible risperidone-induced tardive dystonia. Ann Pharmacother 2000; 34: 1487–8

    PubMed  CAS  Google Scholar 

  63. Campbell M. Risperidone-induced tardive dyskinesia in first-episode psychotic patients. J Clin Psychopharmacol 1999; 19: 276–7

    Article  PubMed  CAS  Google Scholar 

  64. Friedman JH. Rapid onset tardive dyskinesia (‘fly catcher tongue’) in a neuroleptically I patient induced by risperidone. Med Health R I 1998; 81: 271–2

    PubMed  CAS  Google Scholar 

  65. Rangwani SR, Gupta S, Burke WJ, et al. Improvement of debilitating tardive dyskinesia with risperidone. Ann Clin Psychiatry 1996; 8: 27–9

    Article  PubMed  CAS  Google Scholar 

  66. Chong SA, Remington G, Tan CH. Risperidone treatment of tardive dyskinesia and dystonia. J Clin Psychiatry 1999; 60: 340–1

    Article  PubMed  CAS  Google Scholar 

  67. Yoshida K, Higuchi H, Hishikawa Y. Marked improvement of tardive dystonia after replacing haloperidol with risperidone in a schizophrenic patient. Clin Neuropharmacol 1998; 21: 68–9

    PubMed  CAS  Google Scholar 

  68. Kooptiwoot S, Settachan T. Improvement of tardive dyskinesia with risperidone: a case report. J Med Assoc Thai 2000; 83: 1430–2

    PubMed  CAS  Google Scholar 

  69. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995; 15Suppl. 1: 36S–44S

    Article  PubMed  CAS  Google Scholar 

  70. Lemmens P, Brecher M, Van Baelen B. A combined analysis of double-blind studies with risperidone vs placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand 1999; 99: 160–70

    Article  PubMed  CAS  Google Scholar 

  71. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16–22

    Article  PubMed  CAS  Google Scholar 

  72. Jeste DV, Lacro JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999; 47: 716–9

    PubMed  CAS  Google Scholar 

  73. Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000; 157: 1150–5

    Article  PubMed  CAS  Google Scholar 

  74. Tran PV, Dellva MA, Tollefson GD, et al. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997; 58: 205–11

    Article  PubMed  CAS  Google Scholar 

  75. Costa e Silva JA, Alvarez N, Mazzotti G, et al. Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America. J Clin Psychopharmacol 2001; 21: 375–81

    Article  PubMed  Google Scholar 

  76. Vazquez-Barquero JL. Tardive dyskinesia associated with olanzapine [letter]. Ann Intern Med 1999; 131: 72

    PubMed  Google Scholar 

  77. Woods SW. Olanzapine and tardive dyskinesia. Br J Psychiatry 1999; 175: 391–2

    Article  PubMed  CAS  Google Scholar 

  78. Gunal DI, Onultan O, Afsar N, et al. Tardive dystonia associated with olanzapine therapy. Neurol Sci 2001; 22: 331–2

    Article  PubMed  CAS  Google Scholar 

  79. Ananth J, Kenan J. Tardive dyskinesia associated with olanzapine monotherapy [letter]. J Clin Psychiatry 1999; 60: 870

    Article  PubMed  CAS  Google Scholar 

  80. Littrell KH, Johnson CG, Littrell S, et al. Marked reduction of tardive dyskinesia with olanzapine. Arch Gen Psychiatry 1998; 55: 279–80

    Article  PubMed  CAS  Google Scholar 

  81. Almeida OP. Olanzapine for the treatment of tardive dyskinesia. J Clin Psychiatry 1998; 59: 380–1

    Article  PubMed  CAS  Google Scholar 

  82. Jaffe ME, Simpson GM. Reduction of tardive dystonia with olanzapine [letter]. Am J Psychiatry 1999; 156: 2016

    PubMed  CAS  Google Scholar 

  83. Soutullo CA, Keck Jr PE, McElroy SL. Olanzapine in the treatment of tardive dyskinesia: a report of two cases. J Clin Psychopharmacol 1999; 19: 100–1

    Article  PubMed  CAS  Google Scholar 

  84. Lykouras L, Malliori M, Christodoulou GN. Improvement of tardive dyskinesia following treatment with olanzapine. Eur Neuropsychopharmacol 1999; 9: 367–8

    PubMed  CAS  Google Scholar 

  85. Khan M, Farver D. Rapid resolution of antipsychotic-induced tardive dyskinesia with olanzapine. S D J Med 2000; 53: 65–7

    PubMed  CAS  Google Scholar 

  86. Haberfellner EM. Remission of tardive dyskinesia after changing from flupenthixol to olanzapine. Eur Psychiatry 2000; 15: 338–9

    Article  PubMed  CAS  Google Scholar 

  87. Raja M, Azzoni A, Maisto G. Three cases of improvement of tardive dyskinesia following olanzapine treatment. Int J Neuropsychopharmcol 1999; 2: 333–4

    Article  Google Scholar 

  88. Esel E, Turan MT, Sofuoglu S, et al. Improvement of tardive dyskinesia in a bipolar patient with olanzapine. Eur Psychiatry 2000; 15: 438–9

    Article  PubMed  CAS  Google Scholar 

  89. Agarwal V, Kumar P. Olanzapine in the treatment of tardive dyskinesia: a report of 2 cases. J Clin Psychiatry 2001; 62: 298–9

    Article  PubMed  CAS  Google Scholar 

  90. Lucetti C, Bellini G, Nuti A, et al. Treatment of patients with tardive dystonia with olanzapine. Clin Neuropharmacol 2002; 25: 71–4

    Article  PubMed  CAS  Google Scholar 

  91. Truol S, Von Hippel C, Raape J, et al. Improvement of tardive dyskinesia after treatment with olanzapine [in German]. Psychiatr Prax 2002; 29: 315–7

    Article  PubMed  Google Scholar 

  92. Kucerova H. Olanzapine and improvement of tardive dyskinesia. Eur Psychiatry 2002; 17: 421–4

    Article  PubMed  Google Scholar 

  93. Tollefson GD, Beasley Jr CM, Tamura RN, et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997; 154: 1248–54

    PubMed  CAS  Google Scholar 

  94. Beasley CM, Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999; 174: 23–30

    Article  PubMed  CAS  Google Scholar 

  95. Arvanitis LA, Miller BG. Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42: 233–46

    Article  PubMed  CAS  Google Scholar 

  96. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997; 54: 549–57

    Article  PubMed  CAS  Google Scholar 

  97. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000; 57: 553–9

    Article  PubMed  CAS  Google Scholar 

  98. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 2001; 158: 360–9

    Article  PubMed  CAS  Google Scholar 

  99. Ghaemi SN, Ko JY. Quetiapine-related tardive dyskinesia [letter]. Am J Psychiatry 2001; 158: 1737

    Article  PubMed  CAS  Google Scholar 

  100. Ghelber D, Belmaker RH. Tardive dyskinesia with quetiapine. Am J Psychiatry 1999; 156: 796–7

    PubMed  CAS  Google Scholar 

  101. Alptekin K, Kivircik BB. Quetiapine-induced improvement of tardive dyskinesia in three patients with schizophrenia. Int Clin Psychopharmacol 2002; 17: 263–4

    Article  PubMed  CAS  Google Scholar 

  102. Farah A. Reduction of tardive dyskinesia with quetiapine. Schizophr Res 2001; 47: 309–10

    Article  PubMed  CAS  Google Scholar 

  103. Vesely C, Kufferle B, Brucke T, et al. Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine. Int Clin Psychopharmacol 2000; 15: 57–60

    Article  PubMed  CAS  Google Scholar 

  104. Keck Jr P, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998; 140: 173–84

    Article  CAS  Google Scholar 

  105. Goff DC, Posever T, Herz L, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998; 18: 296–304

    Article  PubMed  CAS  Google Scholar 

  106. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999; 20: 491–505

    Article  PubMed  CAS  Google Scholar 

  107. Hirsch SR, Kissling W, Bauml J, et al. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002; 63: 516–23

    Article  PubMed  CAS  Google Scholar 

  108. Rosenquist KJ, Walker SS, Ghaemi SN. Tardive dyskinesia and ziprasidone [letter]. Am J Psychiatry 2002; 159: 1436

    Article  PubMed  Google Scholar 

  109. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763–71

    Article  PubMed  CAS  Google Scholar 

  110. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61: 123–36

    Article  PubMed  Google Scholar 

  111. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39: 486–7

    PubMed  CAS  Google Scholar 

  112. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 1993; 50: 723–33

    Article  PubMed  CAS  Google Scholar 

  113. Kane JM, Weinhold P, Kinon B, et al. Prevalence of abnormal involuntary movements (“spontaneous dyskinesias”) in the normal elderly. Psychopharmacology 1982; 77: 105–8

    Article  PubMed  CAS  Google Scholar 

  114. Klawans HL, Barr A. Prevalence of spontaneous lingual-facial-buccal dyskinesias in the elderly. Neurology 1982; 32: 558–9

    Article  PubMed  CAS  Google Scholar 

  115. Yassa R, Camille Y, Belzile L. Tardive dyskinesia in the course of antidepressant therapy: a prevalence study and review of the literature. J Clin Psychopharmacol 1987; 7: 243–6

    Article  PubMed  CAS  Google Scholar 

  116. Clayton AH. Antidepressant-induced tardive dyskinesia: review and case report. Psychopharmacol Bull 1995; 31: 259–64

    PubMed  CAS  Google Scholar 

  117. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996; 57: 449–54

    Article  PubMed  CAS  Google Scholar 

  118. Bartzokis G, Beckson M, Wirshing DA, et al. Choreoathetoid movements in cocaine dependence. Biol Psychiatry 1999; 45: 1630–5

    Article  PubMed  CAS  Google Scholar 

  119. Sachdev PS. The current status of tardive dyskinesia. Aust N Z J Psychiatry 2000; 34: 355–69

    Article  PubMed  CAS  Google Scholar 

  120. Bobes J, Rejas J, Garcia-Garcia M, et al. Frequency of extrapyramidal adverse reactions in schizophrenia outpatients treated with risperidone, olanzapine, quetiapine or haloperidol. Clin Drug Invest 2002; 22: 609–22

    Article  CAS  Google Scholar 

  121. Schillevoort I, de Boer A, Herings RM, et al. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine. Ann Pharmacother 2001; 35: 1517–22

    Article  PubMed  CAS  Google Scholar 

  122. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51–68

    Article  PubMed  CAS  Google Scholar 

  123. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414–25

    Article  PubMed  Google Scholar 

  124. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001; 158: 765–74

    Article  PubMed  CAS  Google Scholar 

  125. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17: 407–18

    Article  PubMed  CAS  Google Scholar 

  126. Klieser E, Lehmann E, Kinzler E, et al. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychoparmacol 1995; 15Suppl. 1: 45S–51S

    Article  CAS  Google Scholar 

  127. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001; 23: 1839–54

    Article  PubMed  CAS  Google Scholar 

  128. Jeste DV, Wyatt RJ. Therapeutic strategies against tardive dyskinesia: two decades of experience. Arch Gen Psychiatry 1982; 39: 803–16

    Article  PubMed  CAS  Google Scholar 

  129. Newton JE, Cannon DJ, Couch L, et al. Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients. J Clin Psychiatry 1989; 50: 132–5

    PubMed  CAS  Google Scholar 

  130. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45: 79–91

    Article  PubMed  CAS  Google Scholar 

  131. Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990; 47: 754–8

    Article  PubMed  Google Scholar 

  132. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991; 48: 739–45

    Article  PubMed  CAS  Google Scholar 

  133. Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry 2002; 10: 280–91

    Article  PubMed  Google Scholar 

  134. Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull 1997; 23: 583–609

    Article  PubMed  CAS  Google Scholar 

  135. Soares KV, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2001; 4: CD000209

    Google Scholar 

  136. Morris MC, Evans DA, Bienias JL, et al. Vitamin E and cognitive decline in older persons. Arch Neurol 2002; 59: 1125–32

    Article  PubMed  Google Scholar 

  137. Miller CH, Fleischhacker WW. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf 2000; 22: 73–81

    Article  PubMed  CAS  Google Scholar 

  138. Soares KV, McGrath JJ. The treatment of tardive dyskinesia: a systematic review and meta-analysis. Schizophr Res 1999; 39: 1–16

    Article  PubMed  CAS  Google Scholar 

  139. Wirshing WC, Freidenberg DL, Cummings JL, et al. Effects of anticholinergic agents on patients with tardive dyskinesia and concomitant drug-induced parkinsonism. J Clin Psychopharmacol 1989; 9: 407–11

    Article  PubMed  CAS  Google Scholar 

  140. Lohr JB, Cadet JL, Lohr MA, et al. Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms. Schizophr Bull 1988; 14: 291–6

    PubMed  CAS  Google Scholar 

  141. Elkashef AM, Ruskin PE, Bacher N, et al. Vitamin E in the treatment of tardive dyskinesia. Am J Psychiatry 1990; 147: 505–6

    PubMed  CAS  Google Scholar 

  142. Junker D, Steigleider P, Gattaz WF. Alpha-tocopherol in the treatment of tardive dyskinesia [letter]. Clin Neuropharmacol 1992; 15Suppl. 1: 639

    Article  Google Scholar 

  143. Akhtar S, Jajor TR, Kumar S. Vitamin E in the treatment of tardive dyskinesia. J Postgrad Med 1993; 39: 124–6

    PubMed  CAS  Google Scholar 

  144. Dabiri LM, Pasta D, Darby JK, et al. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. Am J Psychiatry 1994; 151: 925–6

    PubMed  CAS  Google Scholar 

  145. Adler LA, Edson R, Lavori P, et al. Long-term treatment effects of vitamin E for tardive dyskinesia. Biol Psychiatry 1998; 43: 868–72

    Article  PubMed  CAS  Google Scholar 

  146. Sajjad SH. Vitamin E in the treatment of tardive dyskinesia: a preliminary study over 7 months at different doses. Int Clin Psychopharmacol 1998; 13: 147–55

    Article  PubMed  CAS  Google Scholar 

  147. Egan MF, Hyde TM, Albers GW, et al. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 1992; 149: 773–7

    PubMed  CAS  Google Scholar 

  148. Adler LA, Peselow E, Rotrosen J, et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 1993; 150: 1405–7

    PubMed  CAS  Google Scholar 

  149. Lohr JB, Caligiuri MP. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry 1996; 57: 167–73

    PubMed  CAS  Google Scholar 

  150. Shriqui CL, Bradwejn J, Annable L, et al. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. Am J Psychiatry 1992; 149: 391–3

    PubMed  CAS  Google Scholar 

  151. Lam LC, Chiu HF, Hung SF. Vitamin E in the treatment of tardive dyskinesia: a replication study. J Nerv Ment Dis 1994; 182: 113–4

    Article  PubMed  CAS  Google Scholar 

  152. Dorevitch A, Kalian M, Shlafman M, et al. Treatment of long-term tardive dyskinesia with vitamin E. Biol Psychiatry 1997; 41: 114–6

    Article  PubMed  CAS  Google Scholar 

  153. Schmidt M, Meister P, Baumann P. Treatment of tardive dyskinesia with vitamin E. Eur Psychiatry 1991; 6: 210–07

    Google Scholar 

  154. Adler R, Rotrosen J, Edson R, et al. Vitamin E treatment for tardive dyskinesia. Arch Gen Psychiatry 1999; 56: 836–41

    Article  PubMed  CAS  Google Scholar 

  155. Barak Y, Swartz M, Shamir E, et al. Vitamin E (alpha-tocopherol) in the treatment of tardive dyskinesia: a statistical metaanalysis. Ann Clin Psychiatry 1998; 10: 101–5

    PubMed  CAS  Google Scholar 

  156. Soares KV, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2000; 2: CD000209

    Google Scholar 

  157. Elkashef AM, Wyatt RJ. Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E. Schizophr Bull 1999; 25: 731–40

    Article  PubMed  CAS  Google Scholar 

  158. Goff DC, Renshaw PF, Sarid-Segal O, et al. A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. Biol Psychiatry 1993; 33: 700–6

    Article  PubMed  CAS  Google Scholar 

  159. Shamir E, Barak Y, Shalman I, et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 2001; 58: 1049–52

    Article  PubMed  CAS  Google Scholar 

  160. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989; 251: 238–46

    PubMed  CAS  Google Scholar 

  161. Wirshing DA, Pierre JM, Erhart SM, et al. Understanding the new and evolving profile of adverse drug effects in schizophrenia. Psychiatr Clin North Am 2003; 26: 165–90

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The author has been a speaker for Janssen, Bristol Myers Squibb, Pfizer, Eli Lilly, AstraZeneca; a consultant for Pfizer, Bristol Myers Squibb; and has received grants from Cephalon.

Author information

Authors and Affiliations

  1. David Geffen School of Medicine at UCLA and VA Greater Los Angeles Healthcare System, 11301 Wilshire Boulevard, Building 210 Room 15, Los Angeles, California, 90073, USA

    Joseph M. Pierre

Authors
  1. Joseph M. Pierre
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph M. Pierre.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pierre, J.M. Extrapyramidal Symptoms with Atypical Antipsychotics. Drug-Safety 28, 191–208 (2005). https://doi.org/10.2165/00002018-200528030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200528030-00002

Keywords

Search

Navigation